Evidence map›Paper›PMID 33693999›Full record

ReviewCurrent pain and headache reports2021

Recent Advances in the Treatment of Opioid Use Disorder.

Sumanth Kuppalli, Raghav Seth, Vwaire Orhurhu, Ivan Urits, Alan D Kaye, Corey Hunter, Amitabh Gulati, Peju Adekoya, Adam M Kaye, Mark R Jones

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current pain and headache reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sumanth KuppalliBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Raghav SethBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Vwaire OrhurhuMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Ivan UritsSouthcoast Health, Southcoast Health Physicians Group, Fall River, MA, USA.
Alan D KayeDepartment of Anesthesiology, Louisiana State University Health Shreveport, Shreveport, LA, USA.
Corey HunterAinsworth Institute of Pain Management, New York, NY, USA.
Amitabh GulatiMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Peju AdekoyaDepartments of Anesthesiology and Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Adam M KayeThomas J. Long School of Pharmacy and Health Sciences, Department of Pharmacy Practice, University of the Pacific, Stockton, CA, USA.
Mark R JonesDepartment of Anesthesiology, Weill Cornell Medical College, New York, NY, USA. mrj9011@NYP.org.ORCID http://orcid.org/0000-0002-4781-2167

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewOpioid use disorder (OUD) remains a national epidemic with an immense consequence to the United States' healthcare system. Current therapeutic options are limited by adverse effects and limited efficacy. RECENT

findingsRecent advances in therapeutic options for OUD have shown promise in the fight against this ongoing health crisis. Modifications to approved medication-assisted treatment (MAT) include office-based methadone maintenance, implantable and monthly injectable buprenorphine, and an extended-release injectable naltrexone. Therapies under investigation include various strategies such as heroin vaccines, gene-targeted therapy, and biased agonism at the G protein-coupled receptor (GPCR), but several pharmacologic, clinical, and practical barriers limit these treatments' market viability. This manuscript provides a comprehensive review of the current literature regarding recent innovations in OUD treatment.

Indexed as

Analgesics, OpioidBuprenorphineDelayed-Action PreparationsDrug ImplantsHumansInjections, IntramuscularMethadoneMolecular Targeted TherapyNaltrexoneNarcotic AntagonistsOpiate Substitution TreatmentOpioid-Related DisordersReceptors, G-Protein-CoupledReceptors, Opioid, muSecologanin Tryptamine AlkaloidsThiophenesAnalgesics, OpioidBuprenorphineDelayed-Action PreparationsDrug ImplantsMethadonemitragynineNaltrexoneNarcotic AntagonistsOREX-1019PZM21 compoundReceptors, G-Protein-CoupledReceptors, Opioid, muSecologanin Tryptamine AlkaloidsThiophenesUreaVaccinesOpioid epidemicOpioidsOpioid use disorderSubstance abuse

Identifiers

PMID33693999

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.